A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
The purpose of this study is to see if we lower the chance of AML returning or getting worse by adding a new drug to the usual combination of drugs.
- IRB Number: 1904708908 (A041701)
- Research Study Identifier: TX10536
- Principal Investigator: Larry Cripe, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required